Delivery of MiR-34a by Chitosan/PLGA Nanoplexes for the Anticancer Treatment of Multiple Myeloma

Overview

Journal Sci Rep

Specialty Science

Date 2015 Dec 2

PMID 26620594

Citations 67

Authors

Donato Cosco

Felisa Cilurzo

Jessica Maiuolo

Cinzia Federico

Maria Teresa Di Martino

Maria Chiara Cristiano

Pierfrancesco Tassone

Massimo Fresta

Donatella Paolino

Affiliations

Soon will be listed here.

Abstract

The encapsulation of miR-34a into chitosan/PLGA nanoparticles in order to obtain nanoplexes useful for the modulation of the biopharmaceutical features of the active compound was studied. The nanoplexes were obtained through nanoprecipitation and were characterized by a mean diameter of ~160 nm, a good size distribution and a positive surface charge. The structure of the nanoparticles allowed a high level of entrapment efficiency of the miR-34a and provided protection of the genetic material from the effects of RNase. A high degree of transfection efficiency of the nanoplexes and a significant in vitro antitumor effect against multiple myeloma cells was demonstrated. The therapeutic properties of the nanoplexes were evaluated in vivo against human multiple myeloma xenografts in NOD-SCID mice. The systemic injection of miR-34a mimic-loaded nanoparticles significantly inhibited tumor growth and translated into improved survival of the laboratory mice. RT-PCR analysis carried out on retrieved tumors demonstrated the presence of a high concentration of miR-34a mimics. The integrity of the nanoplexes remained intact and no organ toxicity was observed in treated animals.

Citing Articles

Recent advances in targeted drug delivery systems for multiple myeloma.

Pant A, Laliwala A, Holstein S, Mohs A J Control Release. 2024; 376:215-230.

PMID: 39384153 PMC: 11611669. DOI: 10.1016/j.jconrel.2024.10.003.

Polymeric Vehicles for Nucleic Acid Delivery: Enhancing the Therapeutic Efficacy and Cellular Uptake.

Gupta P, Sharma A, Mittal V Recent Adv Drug Deliv Formul. 2024; 18(4):276-293.

PMID: 39356099 DOI: 10.2174/0126673878324536240805060143.

Advances in nucleic acid therapeutics: structures, delivery systems, and future perspectives in cancer treatment.

Zhang L, Lou W, Wang J Clin Exp Med. 2024; 24(1):200.

PMID: 39196428 PMC: 11358240. DOI: 10.1007/s10238-024-01463-4.

Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions.

Li S, Wang H, Xiong S, Liu J, Sun S Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065683 PMC: 11279695. DOI: 10.3390/ph17070832.

Multifunctional elastin-like polypeptide nanocarriers for efficient miRNA delivery in cancer therapy.

Hong J, Sim D, Lee B, Sarangthem V, Park R J Nanobiotechnology. 2024; 22(1):293.

PMID: 38802812 PMC: 11131307. DOI: 10.1186/s12951-024-02559-5.

References

Di Martino M, Gulla A, Gallo Cantafio M, Altomare E, Amodio N, Leone E . In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS One. 2014; 9(2):e89659. PMC: 3931823. DOI: 10.1371/journal.pone.0089659. View

Chan B, Manley J, Lee J, Singh S . The emerging roles of microRNAs in cancer metabolism. Cancer Lett. 2014; 356(2 Pt A):301–8. DOI: 10.1016/j.canlet.2014.10.011. View

Vidigal J, Ventura A . The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol. 2014; 25(3):137-47. PMC: 4344861. DOI: 10.1016/j.tcb.2014.11.004. View

Rossi M, Amodio N, Di Martino M, Tagliaferri P, Tassone P, Cho W . MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. Curr Pharm Biotechnol. 2014; 15(5):459-67. DOI: 10.2174/1389201015666140519104743. View

Tassone P, Neri P, Burger R, Di Martino M, Leone E, Amodio N . Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets. 2012; 12(7):814-22. PMC: 3587184. DOI: 10.2174/156800912802429292. View

Celia C, Malara N, Terracciano R, Cosco D, Paolino D, Fresta M . Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells. Nanomedicine. 2008; 4(2):155-66. DOI: 10.1016/j.nano.2008.02.003. View

Yin H, Kanasty R, Eltoukhy A, Vegas A, Dorkin J, Anderson D . Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15(8):541-55. DOI: 10.1038/nrg3763. View

Wolfram J, Suri K, Yang Y, Shen J, Celia C, Fresta M . Shrinkage of pegylated and non-pegylated liposomes in serum. Colloids Surf B Biointerfaces. 2013; 114:294-300. PMC: 3884810. DOI: 10.1016/j.colsurfb.2013.10.009. View

Wolfram J, Yang Y, Shen J, Moten A, Chen C, Shen H . The nano-plasma interface: Implications of the protein corona. Colloids Surf B Biointerfaces. 2014; 124:17-24. PMC: 4152388. DOI: 10.1016/j.colsurfb.2014.02.035. View

10.

Mahindra A, Laubach J, Raje N, Munshi N, Richardson P, Anderson K . Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012; 9(3):135-43. DOI: 10.1038/nrclinonc.2012.15. View

11.

Yousefi A, Storm G, Schiffelers R, Mastrobattista E . Trends in polymeric delivery of nucleic acids to tumors. J Control Release. 2013; 170(2):209-18. DOI: 10.1016/j.jconrel.2013.05.040. View

12.

Merkel O, Kissel T . Quo vadis polyplex?. J Control Release. 2014; 190:415-23. DOI: 10.1016/j.jconrel.2014.06.009. View

13.

Tassone P, Neri P, Carrasco D, Burger R, Goldmacher V, Fram R . A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood. 2005; 106(2):713-6. PMC: 1895174. DOI: 10.1182/blood-2005-01-0373. View

14.

Shi S, Han L, Deng L, Zhang Y, Shen H, Gong T . Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release. 2014; 194:228-37. DOI: 10.1016/j.jconrel.2014.09.005. View

15.

Misso G, Di Martino M, De Rosa G, Farooqi A, Lombardi A, Campani V . Mir-34: a new weapon against cancer?. Mol Ther Nucleic Acids. 2014; 3:e194. PMC: 4222652. DOI: 10.1038/mtna.2014.47. View

16.

Paolino D, Cosco D, Gaspari M, Celano M, Wolfram J, Voce P . Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes. Biomaterials. 2014; 35(25):7101-9. DOI: 10.1016/j.biomaterials.2014.04.088. View

17.

Paolino D, Cosco D, Celano M, Moretti S, Puxeddu E, Russo D . Gemcitabine-loaded biocompatible nanocapsules for the effective treatment of human cancer. Nanomedicine (Lond). 2012; 8(2):193-201. DOI: 10.2217/nnm.12.101. View

18.

Moloughney J, Weisleder N . Poloxamer 188 (p188) as a membrane resealing reagent in biomedical applications. Recent Pat Biotechnol. 2012; 6(3):200-11. PMC: 3756676. DOI: 10.2174/1872208311206030200. View

19.

Licciardi M, Paolino D, Celia C, Giammona G, Cavallaro G, Fresta M . Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs. Biomaterials. 2010; 31(28):7340-54. DOI: 10.1016/j.biomaterials.2010.05.060. View

20.

Celia C, Cilurzo F, Trapasso E, Cosco D, Fresta M, Paolino D . Ethosomes® and transfersomes® containing linoleic acid: physicochemical and technological features of topical drug delivery carriers for the potential treatment of melasma disorders. Biomed Microdevices. 2011; 14(1):119-30. DOI: 10.1007/s10544-011-9590-y. View